Introduction {#sec1-1}
============

In the present era, due to modern life style, hectic work schedule, stress, and many such reasons, incidence of disease is increasing, and one of them is *Amavata*, which can be compared with rheumatoid arthritis (RA) due to its clinical presentation. The disease is being chosen for the study due to its widespread clinical spectrum, increased prevalence, and lack of effective medicaments. Prevalence of the disease is approximately 0.8% of the population and about 80% of people develop this disease between the age of 35 and 50 years.\[[@ref1]\]

According to the nature of disease, it is essential to plan such therapy which has *Ama* and *Vatahara* properties. The line of treatment described for the disease in *Chakradatta Amavatachikisa Prakarana* includes *Langhana, Swedana* use of *Tikta* and *Katu* drugs and if needed *Virechana* and *Basti*.\[[@ref2]\] This study has been under taken to evaluate role of *Shamana* drug along with *Shodhana* therapy *(Virechana Basti*). Hence, in the present study, *"Alambushadi Ghana Vati"* has been selected as *Shamana Yoga* while "*Vaitarana Basti"* has been selected for study as *Samshodhana* process.

Aims and Objectives {#sec2-1}
-------------------

Clinical evaluation of efficacy of *Alambushadi Ghana Vati* and *Vaitarana Basti* in the management of *Amavata* (RA).

Materials and Methods {#sec1-2}
=====================

Selection of patient {#sec2-2}
--------------------

Thirty patients of *Amavata* were selected from *Kayachikitsa* OPD and IPD of National Institute of Ayurveda, Jaipur. The case selection was regardless of age, sex, occupation and socio-economic conditions. Both acute and chronic phases of *Amavata* patients were taken for the study, following the ACR criteria of the diagnosis of RA in modern medicine and the clinical features of *Amavata* described in *Madhava Nidana*.\[[@ref3]\]

Study design {#sec2-3}
------------

Present study is single center, open labeled randomized (lottery method) clinical trial.

Inclusion criteria {#sec2-4}
------------------

The patients between the age group of 16--70 years of either sex presenting with the clinical features of *Amavata* like pain, stiffness and swelling in multiple joints along with features of *Ama* like loss of appetite, indigestion and feverPatient diagnosed for RA on the basis ACR criteriaPatient of *Amavata* (RA) having chronicity \<10 years.

Exclusion criteria {#sec2-5}
------------------

Patients of age below 16 years and above 70 years of either sexChronicity of *Amavata* more than 10 yearsPatients having severe crippling deformitiesPatients suffering from paralysisPatients having neoplasm of spine, gout, ankylosing spondylitis, traumatic arthritis, and pyogenic osteomyelitisPatients having associated cardiac disease, pulmonary tuberculosis, diabetes mellitus, malignant hypertension, renal function impairment, etc.Patients with extremely reduced joint spacePatients with bone deformity.Pregnant women and lactating motherPatients contraindicated for *Basti* as mentioned in *Samhitas*.

Grouping {#sec2-6}
--------

A total of 30 clinically diagnosed and registered patients of *Amavata* were divided randomly by lottery method into two groups. Each group had 15 patients.

Group A: 15 clinically diagnosed patients of *Amavata* were treated with *Alambushadi Ghana Vati* two tablets (each 500 mg) three times in a day with lukewarm water after meal for 30 days.

Group B: 15 clinically diagnosed patients of *Amavata* were treated with *Alambushadi Ghana Vati* two tablets (each 500 mg) three times in a day with lukewarm water after meal for 30 days along with *Vaitarana Basti* which was given on alternate day (15 *Basti*) simultaneously. *Vaitarana Basti* (approximately 200--250 ml), after the meal and *Anuvasana Basti* (approximately 60--80 ml), after the meal (It was given only to the patients who presented with symptoms of *Vata* aggravation. It consisted of *Tila Taila* and one pinch of *Saindhava* mixed well. It was given in the dose of 60--80 ml whenever the patients developed *Vata Vriddhi Lakshana* while receiving *Vaitarana Basti*.

Drugs and method of its preparation {#sec2-7}
-----------------------------------

*Alambushadi Ghana Vati* selected in this trial was taken from *Chakradutta Amavatachikitsa Prakarana*\[[@ref4]\] which contains *Alambhusha* (*Lajjalu*) (*Mimosa pudica* Linn.), *Gokshur* (*Tribulus terrestris* Linn.)*, Haritaki* (*Terminalia chebula* Retz.)*, Bibhitaki* (*Terminalia bellerica* Roxb.)*, Amalaki* (*Emblica officinalis* Gaertn.)*, Shunthi* (*Zingiber officinale* Roscoe)*, Amrita* (*Tinospora cordifolia* (Thunb.) Miers)*, Trivrutta* (*Operculina turpethum* Linn.) in the proportion of 1:2:3:4:5:6:7:28. *Alambushadi Ghana Vati* was made of 500 mg each *Vati*. The materials were procured and prepared in GMP certified pharmacy of the institute (Drug Batch No. A0281).

Ingredients of *Vaitarana Basti* {#sec2-8}
--------------------------------

*Amalika* *(Emali)* (*Tamarindus indica* Linn.)*, Guda, Saindhava, Gomutra*, and *Tila Taila* (*Sesamum indicum* Linn.) in the proportion of 4:2:1:16.

### Preparation of Vaitarana Basti {#sec3-1}

Initially, 20 g (1 *Shukti*) of jaggery (*Guda*) was mixed uniformly with equal quantity of lukewarm water and 10 g (1 *Karsha*) of *Saindhava* was added. Thereafter, *Tila Taila* was added till the mixture become homogenous (approximately 30 ml). To this 40 g (1 *Pala*) of *Emali Kalka* was added carefully and then finally, 160 ml (1 *Kudava)* of *Gomutra* was added slowly and mixing untill uniform *Basti Dravya* was obtained. That was then filtered and *Basti Dravya* was made lukewarm by keeping it into hot water. *Basti* was given by proper method in the left lateral position by *Basti Yantra*, after meals in morning hours.

Criteria for assessment {#sec2-9}
-----------------------

### Subjective parameters {#sec3-2}

Assessment of sign and symptoms was done pre- and post-trial on severity grading scale for various aspects of disease as developed by Prof. Ram Kishor Joshi *et al*. \[Tables [1](#T1){ref-type="table"}--[14](#T14){ref-type="table"}\].

###### 

Severity grading scale
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Grading of stiffness present in the joint
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Grading of swelling present in the joint
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Grading of movement
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Grading of tenderness present in the joint
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Grading of body ache (*Angamarda*)
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###### 

*Aruchi* (anorexia)
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###### 

Grading of *Trishana* (excessive thirst)
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###### 

*Alasya* (laziness)
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*Gaurava* (heaviness)
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###### 

*Jwara* (fever)
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###### 

*Apaka* (indigestion of food)

![](AYU-37-105-g012)

###### 

*Bahumootrata* (frequency of urine micturition per 2 h)
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###### 

Grading of developed for assessment of in clinical manifestation
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### Investigations {#sec3-3}

For the assessment of effect of therapy and to rule out side effect if any, following investigation were done:

Hematological- Hb gm%, total leukocytes count (TLC), differential leukocyte count (DLC), erythrocyte sedimentation rate (ESR), serum. uric acid, fasting blood sugar level (FBS), RA factor, C-reactive protein (CRP) test, antistreptolysin O (ASLO) titerUrine routine/microscopicRadiological X-ray of affected joints.

In this study, serum uric acid was done to exclude Gout which mimic the RA symptoms and random blood sugar level (RBS) was used for screening patients of diabetes.

Observation {#sec2-10}
-----------

Present study had shown that 50% patients belong to the 3^rd^ to 5^th^ decade of life and were formal. Incidence of disease is notably higher in females (73.33%) than in males (26.67%), i.e., (2.7:1) Majority of the patients (76.67%) belonged to Hindu religion; 80% patients were married. Out of which, maximum 50% patients were housewives, followed by 26.67% laborers; about 50% patients belonged to middle class. 46.67% patients were of *Vata-Kaphaja Prakriti*, 56.67% patients were of *Madhyama Sara*, 43.33% had *Madhyama Samhanana*, 56% patients with *Madhyama Satmya*, 64% patients with *Madhyama Satva*, 53.33% patients showed *Madhyama Ahara Shakti*, 53.33% patients showed *Avara Vyayamashakti*, 50% patients had *Madhyama Koshtha*, whereas 40% patients had *Krura Koshtha* and maximum 60% patients had *Mandagni*. In this type of *Koshtha* and *Agni*, there is predominance of *Vata* and *Kapha Dosha*, which may play important role in developing the pathogenesis of *Amavata*.

Maximum 40% of the patients had duration of illness for less then \<2 years; 46.67% patients were of taking allopathic medicine; 43.33% patients had positive family history of the disease; maximum 80% patients had CRP; 20% patients had ASLO titer and 16.67% patients had RA factor positive before the treatment; 100% patients had pain, stiffness, swelling of the affected joints. *Angamarda* and *Jwara* while; 96.99% patients had tenderness of joint. The 86.66% patients had restriction of movement and 80% of the patients had *Alasya*; 76.66% had *Gaurava*;and 60% patients had *Trishana* before the treatment. Maximum 93.33% of the patients had proximal interphalengeal (hand) joint involvement, 90% metacarpophalengeal and 86.66% had distal interphalengeal (hand) joint involvement other joints affected were wrist joint (83.33%), elbow joint (73.33%), shoulder joint (53.33%), ankle joint (60%), knee joint involvement (43%), metatarsophalengeal (73.33%) and tempomandibular joint 16%.

Results {#sec1-3}
=======

Effect of therapy on subjective parameters {#sec2-11}
------------------------------------------

In Group A, highly significant (HS) results (*P* \< 0.0001) in subjective parameters-- like pain in joint (68.35%), stiffness of joint (56.26%), swelling of joint (66.97%), restriction of movement (45.45%), tenderness at joint (59.99%), *Angamarda* (57.59%), *Aruchi* (*60.88%), Gaurava* (44.44%), *Jwara* (66.69%), *Apaka* (59.99%) and *Bahumootrata* 59.98% was found. In case of other subjective parameters, i.e., *Alasya*, there was significant result (*P* \< 0.05) with percentage relief of 44.44% and *Trishna* there were nonsignificant results (*P* \> 0.05) with percentage relief of 19.99%. In Group B, highly significant improvement results (*P* \< 0.0001) in all subjective parameters with percentage improvement of pain in joint (77.927%), stiffness of joint (66.67%), swelling of joint (73.11%), restriction of movement (81.80%), tenderness at joint (76.92%), *Angamarda* (81.80%), *Aruchi* (80%), *Trishna* (57.88%), *Alasya* (79.96%), *Gaurava* (74.06%), *Jwara* (78.57%), *Apaka* (81.50%)and *Bahumootrata* 80% was reported \[[Table 15](#T15){ref-type="table"}\].

###### 

Effect of therapy in subjective parameters
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Intergroup comparison of Group A and Group B for subjective parameters {#sec2-12}
----------------------------------------------------------------------

Intergroup comparison showed that there was no major difference in efficacy of trial drug of Groups A and B. However, *Angmarda* (-- *P* \< 0.05) which there was statistically significant difference that there is statistical showed that Group A provided better result than Group B \[[Table 16\]](#T16){ref-type="table"}.

###### 

Intergroup comparison of Group A and Group B for subjective parameters
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Effect of therapy in objective parameters (laboratory investigations) {#sec2-13}
---------------------------------------------------------------------

In Group A -- statistical significant increase Hb% and ESR (*P* \< 0.05) with change of 3.37% and 35.12%, reduction was reported respectively. While other parameter no significant chages were found. However, it remained within normal range.

In Group B, statically highly significant reduction in ESR was found similarly, significant reduction in TLC (13.14%) was also found \[Table [17](#T17){ref-type="table"}--[18](#T18){ref-type="table"}\].

###### 

Effect of therapy on haematological parameters
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###### 

Inter group comparison on haematological parameters
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Qualitative analysis of RA factor and CRP was done, and on applying statistical analysis, no significant result was found.

Overall effect of therapy {#sec2-14}
-------------------------

In Group A, excellent relief was found in 6.66% of patients, while significant relief in 46.66%, moderate relief in 33.33%, whereas mild relief in 13.33% of the patients, while in Group B -- excellent relief was found in 20% of patients, while significant relief in 60%, moderate relief in 13.33%, whereas mild relief in 6.66% of the patients \[[Table 19](#T19){ref-type="table"}\].

###### 

Overall effect of therapy of the Group A and Group B
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Discussion {#sec1-4}
==========

Ingredients of *Alambushadi Ghana Vati* are *Alambhusha* (*Lajjalu*), *Gokshur, Haritaki, Bibhitaki, Amalaki, Shunthi, Amrita, Trivrutta* in the proportion of 1:2:3:4:5:6:7:28, i.e., having highest concentration of *Trivrutta* with their *Kapha Vata Shamaka* and *Virechana* properties thus\[[@ref5]\] help in reducing the swelling in the joints.

Also, *Katu, Tikta Rasa* is dominant in this formulation, thus help in digestion of *Ama* and finally in breakage of pathogenesis of disease. Besides this, there is dominancy of *Laghu, Ruksha Gunas* in the *Alambushadi Ghana Vati* which also helps in *Kaphaghna* property. Five *Dravyas* out of eight in the formulation possesses *Laghu* and *Ruksha Guna*. This formulation also dominance of drugs *Ushna Virya* which also helps to pacify the *Vata Dosha*. In addition of six *Dravyas* with *Shothahara* and *Anulomana* property are also present. With these overall effect of these properties of the drugs of *Alambushadi Ghana Vati, Ama* and *Vata Dosha* is treated and thus relief in the cardinal symptoms of the disease was found.

*Guduchi* is also proved to have antirheumatic, anti-inflammatory, and immunomodulatory properties.\[[@ref6]\] While, *Sunthi* is also proved beneficial for rheumatic and musculoskelatal disorders.\[[@ref7]\]*Triphala* has *Rasayana, Tridoshahara*, and *Virechana* properties\[[@ref8]\] which helps in reducing the swelling in the joints. *Gokshura* with its diuretic properties helps to reduce swelling in the joints.\[[@ref9]\]

Probable mode of action of *Vaitarana Basti* {#sec2-15}
--------------------------------------------

*Vaitarana Basti* has been mentioned by *Chakradutta in Niruhadhikar* 73/32. Ingredients of *Vaitarana Basti* are *Amalika* *(Emali), Guda, Saindhava, Gomutra* and *Tila taila* in the proportion of 4:2:1:16. As a whole, the qualities of *Vaitarana Basti* can be considered as *Laghu, Ruksha, Ushna, Tikshna*. Majority of the drugs have *Vata Kapha Shamaka* action. Owing to these properties treatment with the *Basti* has provided significant improvement in sign and symptom of disease. The *Tikshna Guna* of *Basti* helps in overcoming the *Srotodushti* resulting due to *Sanga*, thus help in breaking down the pathogenesis of disease.

*Basti* therapy may be stimulator for many intraluminal, luminal, and whole body functions. *Basti Karma* exerts a more systemic action besides exerting local action of operating through large intestine involving enteric nervous system. Enteric nervous system is a collection of neurons in the gastrointestinal tract (GIT) constituting the brain of gut. Apart from its influence on GIT, enteric nervous system also influences the autonomic nervous system thereby producing systemic affect.\[[@ref10]\]

*Vata* is very important *Dosha* to be managed during treatment of any disease as *Acharya* told that other *Doshas* are handicapped without *Vata Dosha*, and *Basti* is very important therapy to manage *Vata Dosha*, and is called as *Ardha Chikitsa*.\[[@ref11]\]

As a whole, the effect of *Basti* can be summarized as encolonic (action on tissue of colon), endcolonic (action inside colon), and diacolonic (for systemic action). Thus, *Basti Dravya* after reaching to large and small intestine get absorbed from intestine and due to *Laghu, Ushna, Tikshna*, and *Ruksha Guna* of *Vaitarana Basti Dravya*, it breaks the obstructions and expels out the morbid material from all over the body, thus help in breaking down the pathogenesis of disease.

General observation made during the trial {#sec2-16}
-----------------------------------------

During the trial, it was observed that in *Vata Pittaja Prakriti* patients, there was less holding capacity of the *Basti Dravya*. In these patients, the dose of *Gomutra* was lowered along with overall *Basti* quantity to seek the expected resultsAs *Ayurveda* is individualized science (*Ch*. *Su*. 1/24), every individual has different sensitivity for different contents of formulation, hence cases abdominal discomfort was reported in few cases which was managed by reduction in total quantity of the *Basti*Just after *Samyaka Basti Nirharana*, patient felt very light and enthusiastic.

Conclusion {#sec1-5}
==========

Finally, comparing the effect of two therapies, it can be concluded that (*Alambushadi Ghana Vati* along with *Vaitarana Basti*) provided better relief than (*Alambushadi Ghana Vati* alone) in most of the signs and symptoms of the disease at significant level.
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